Thromboxane synthetase inhibition with CGS 13080 improves coronary blood flow after streptokinase-induced thrombolysis
- 9 June 1987
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 113 (6), 1345-1352
- https://doi.org/10.1016/0002-8703(87)90646-6
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- Augmentation of Streptokinase-Induced Thrombolysis by Heparin and ProstacyclinJournal of Cardiovascular Pharmacology, 1985
- The Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1985
- The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion.Circulation, 1984
- Selective and nonselective inhibition of thromboxane formationClinical Pharmacology & Therapeutics, 1984
- The Effects of a New Thromboxane Synthetase Inhibitor, CGS‐13080, in ManThe Journal of Clinical Pharmacology, 1984
- Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical modelsBiochemical and Biophysical Research Communications, 1983
- Cardioprotective Effects of Ibuprofen in Experimental Regional and Global Myocardial IschemiaJournal of Cardiovascular Pharmacology, 1982
- Early phase acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium chloride tissue enzyme staining techniqueAmerican Heart Journal, 1981
- Electrical induction of coronary artery thrombosis in the ambulatory canine: A model for evaluation of anti-thrombotic agentsThrombosis Research, 1980